Herbal medicines for the treatment of cancer chemotherapy-induced side effects

被引:69
作者
Ohnishi, Shunsuke [1 ]
Takede, Hiroshi [2 ]
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido 0600812, Japan
[2] Hokkaido Univ, Fac Pharmaceut Sci, Pathophysiol & Therapeut, Sapporo, Hokkaido 0600812, Japan
基金
日本学术振兴会;
关键词
Kampo; rikkunshito; hangeshashinto; goshajinkigan; chemotherapy-induced side effects; TRADITIONAL JAPANESE MEDICINE; CISPLATIN-INDUCED ANOREXIA; PLACEBO-CONTROLLED TRIAL; INDUCED PERIPHERAL NEUROPATHY; HIGH-DOSE CISPLATIN; HANGE-SHASHIN-TO; DES-ACYL GHRELIN; INDUCED NAUSEA; DOUBLE-BLIND; ORAL MUCOSITIS;
D O I
10.3389/fphar.2015.00014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Accumulating evidence suggests that Japanese herbal medicines, called Kampo, have beneficial effects on cancer chemotherapy induced side effects. Rikkunshito ameliorates cisplatin-induced anorexia through an antagonistic effect on the 5-HT receptors and by increasing the serum ghrelin levels. Hangeshashinto improves irinotecan-induced diarrhea and chemotherapy-induced mucositis by inhibiting the activity of beta-glucuronidase as well as the synthesis of prostaglandin E2. Goshajinkigan prevents oxaliplatin-induced neurotoxicity, possibly through suppressing functional alterations of the transient receptor potential channels. In this review, we will summarize the currently available literature regarding the clinical efficacy and potential mechanisms of Kampo medicines in the treatment of cancer chemotherapy induced side effects.
引用
收藏
页数:5
相关论文
共 67 条
[1]   PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS [J].
ABIGERGES, D ;
CHABOT, GG ;
ARMAND, JP ;
HERAIT, P ;
GOUYETTE, A ;
GANDIA, D .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :210-221
[2]   Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy [J].
Akin, Semiha ;
Can, Gulbeyaz ;
Aydiner, Adnan ;
Ozdilli, Kursat ;
Durna, Zehra .
EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2010, 14 (05) :400-409
[3]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[4]  
[Anonymous], ANN CANC RES THER
[5]   Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis [J].
Aoyama, Toru ;
Nishikawa, Kazuhiro ;
Takiguchi, Nobuhiro ;
Tanabe, Kazuaki ;
Imano, Motohiro ;
Fukushima, Ryoji ;
Sakamoto, Junichi ;
Oba, Mari S. ;
Morita, Satoshi ;
Kono, Toru ;
Tsuburaya, Akira .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) :1047-1054
[6]   IDENTIFICATION OF THE METABOLITES OF IRINOTECAN, A NEW DERIVATIVE OF CAMPTOTHECIN, IN RAT BILE AND ITS BILIARY-EXCRETION [J].
ATSUMI, R ;
SUZUKI, W ;
HAKUSUI, H .
XENOBIOTICA, 1991, 21 (09) :1159-1169
[7]   Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT [J].
Baldanzi, G ;
Filigheddu, N ;
Cutrupi, S ;
Catapano, F ;
Bonissoni, S ;
Fubini, A ;
Malan, D ;
Baj, G ;
Granata, R ;
Broglio, F ;
Papotti, M ;
Surico, N ;
Bussolino, F ;
Isgaard, J ;
Deghenghi, R ;
Sinigaglia, F ;
Prat, M ;
Muccioli, G ;
Ghigo, E ;
Graziani, A .
JOURNAL OF CELL BIOLOGY, 2002, 159 (06) :1029-1037
[8]  
Basch Ethan, 2012, Am Soc Clin Oncol Educ Book, P532, DOI 10.14694/EdBook_AM.2012.32.532
[9]   Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln 14-ghrelin [J].
Bedendi, I ;
Alloatti, G ;
Marcantoni, A ;
Malan, D ;
Catapano, F ;
Ghé, C ;
Deghenghi, R ;
Ghigo, E ;
Muccioli, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 476 (1-2) :87-95
[10]   Oral mucositis in cancer treatment: Natural history, prevention and treatment [J].
da Cruz Campos, Maria Ines ;
Campos, Celso Neiva ;
Aarestrup, Fernando Monteiro ;
Vieira Aarestrup, Beatriz Juliao .
MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) :337-348